4.07
price up icon0.25%   0.01
 
loading
Schlusskurs vom Vortag:
$4.06
Offen:
$4.05
24-Stunden-Volumen:
5,866
Relative Volume:
0.13
Marktkapitalisierung:
$1.45B
Einnahmen:
$842.96M
Nettoeinkommen (Verlust:
$-185.63M
KGV:
-7.7391
EPS:
-0.5259
Netto-Cashflow:
$-228.52M
1W Leistung:
-0.73%
1M Leistung:
+12.12%
6M Leistung:
-3.10%
1J Leistung:
+5.17%
1-Tages-Spanne:
Value
$4.05
$4.08
1-Wochen-Bereich:
Value
$4.03
$4.27
52-Wochen-Spanne:
Value
$2.84
$5.6405

Evotec Se Adr Stock (EVO) Company Profile

Name
Firmenname
Evotec Se Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
4,766
Name
Twitter
Name
Nächster Verdiensttermin
2025-04-17
Name
Neueste SEC-Einreichungen
Name
EVO's Discussions on Twitter

Vergleichen Sie EVO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
EVO
Evotec Se Adr
4.08 1.44B 842.96M -185.63M -228.52M -0.5259
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
143.18 63.86B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.46 41.80B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.205 40.88B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
20.14 22.98B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
449.15 19.53B 3.08B 1.24B 1.07B 25.61

Evotec Se Adr Stock (EVO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-24 Hochstufung Deutsche Bank Sell → Hold
2024-10-07 Herabstufung Jefferies Buy → Hold
2024-08-08 Herabstufung Deutsche Bank Hold → Sell
2024-07-29 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-07-11 Herabstufung Deutsche Bank Buy → Hold
2024-04-12 Hochstufung Deutsche Bank Hold → Buy
2024-01-18 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2023-06-23 Hochstufung Morgan Stanley Equal-Weight → Overweight
2023-06-16 Herabstufung BofA Securities Buy → Neutral
2023-06-08 Hochstufung Citigroup Neutral → Buy
2023-04-04 Hochstufung Morgan Stanley Underweight → Equal-Weight
2022-12-09 Eingeleitet H.C. Wainwright Buy
2022-11-16 Herabstufung Deutsche Bank Buy → Hold
2022-08-10 Herabstufung Morgan Stanley Overweight → Underweight
2022-03-02 Fortgesetzt Cowen Outperform
2022-01-07 Fortgesetzt Citigroup Neutral
Alle ansehen

Evotec Se Adr Aktie (EVO) Neueste Nachrichten

pulisher
Oct 27, 2025

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner - Benzinga

Oct 27, 2025
pulisher
Oct 13, 2025

ETFs Investing in Evotec SE Sponsored ADR Stocks - TradingView

Oct 13, 2025
pulisher
Oct 07, 2025

Evotec (NASDAQ:EVO) versus CASI Pharmaceuticals (NASDAQ:CASI) Critical Survey - Defense World

Oct 07, 2025
pulisher
Sep 07, 2025

Evotec Ag’s Earnings Call: Mixed Sentiments and Strategic Moves - MSN

Sep 07, 2025
pulisher
Aug 28, 2025

Stock Information - Evotec

Aug 28, 2025
pulisher
Aug 28, 2025

Annual General Meeting - Evotec

Aug 28, 2025
pulisher
Aug 14, 2025

Evotec SE ADR earnings missed by $0.07, revenue fell short of estimates - Investing.com South Africa

Aug 14, 2025
pulisher
Aug 14, 2025

Evotec AG Reports Mixed H1 2025 Performance - TipRanks

Aug 14, 2025
pulisher
Aug 11, 2025

Ørsted announces plan for a rights issue with support from the Danish State as majority shareholder and gross proceeds of DKK 60 billion11.08.25NewsARIVA.DE - rova

Aug 11, 2025
pulisher
Aug 02, 2025

Evotec shares drop sharply after lowering 2025 revenue forecast - MSN

Aug 02, 2025
pulisher
Jul 30, 2025

Evotec and Sandoz plan potential sale of Toulouse biologics site By Investing.com - Investing.com South Africa

Jul 30, 2025
pulisher
Jul 30, 2025

Evotec and Sandoz plan potential sale of Toulouse biologics site - Investing.com

Jul 30, 2025
pulisher
Jul 26, 2025

Evotec SE (EVO) Stock Forecasts - Yahoo Finance

Jul 26, 2025
pulisher
Jul 25, 2025

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union - Ariva

Jul 25, 2025
pulisher
Jul 22, 2025

SAP Quarterly Statement Q2 202522.07.25News - Ariva

Jul 22, 2025
pulisher
Jul 21, 2025

Evotec stock tumbles after slashing 2025 revenue guidance - Investing.com Australia

Jul 21, 2025
pulisher
Jul 21, 2025

Evotec stock tumbles after slashing 2025 revenue guidance By Investing.com - Investing.com Canada

Jul 21, 2025
pulisher
Jun 04, 2025

8 New 4-Star Stocks - Morningstar

Jun 04, 2025
pulisher
May 24, 2025

Evotec SE ADR (EVO) Strikes $4.73: The Risk Seems Worthwhile At This Price - Stocksregister

May 24, 2025
pulisher
May 07, 2025

Evotec SE ADR earnings missed by $0.03, revenue fell short of estimates - Investing.com Nigeria

May 07, 2025
pulisher
May 07, 2025

Evotec Ag Earnings Call: Mixed Sentiment Amid Growth - TipRanks

May 07, 2025
pulisher
May 07, 2025

Evotec AG Reports Q1 2025 Earnings and Strategic Progress - TipRanks

May 07, 2025
pulisher
Apr 24, 2025

Evotec shares surge 51% following InvestingPro’s undervalued signal By Investing.com - Investing.com India

Apr 24, 2025
pulisher
Apr 18, 2025

Evotec SE ADR earnings beat by $0.08, revenue topped estimates - Investing.com

Apr 18, 2025
pulisher
Apr 17, 2025

Evotec SE Reports Strong Q4 2024 and New Strategy - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Evotec Ag’s Earnings Call: Growth Amid Challenges - TipRanks

Apr 17, 2025
pulisher
Apr 08, 2025

Bayer, BioNxt Solutions, Evotec – falscher Zoll Alarm bei Pharma und Biotech! Welche Aktien lohnen sich? - kapitalerhoehungen.de

Apr 08, 2025
pulisher
Dec 29, 2024

Evotec: Some Recovery Has Come, But Much More Is Expected - Seeking Alpha

Dec 29, 2024
pulisher
Nov 25, 2024

Markets Brief: Are Bank Stocks Expensive? - Morningstar

Nov 25, 2024
pulisher
Nov 15, 2024

Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - Baystreet.ca

Nov 15, 2024
pulisher
Aug 23, 2024

Investor Relations - Evotec

Aug 23, 2024
pulisher
Aug 14, 2024

Earnings call: Evotec SE revises 2024 outlook amid market challenges - Investing.com

Aug 14, 2024
pulisher
Aug 13, 2024

Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar Canada

Aug 13, 2024
pulisher
Jun 06, 2024

Healthcare Sector - Morningstar

Jun 06, 2024
pulisher
May 23, 2024

Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com India

May 23, 2024
pulisher
Apr 25, 2024

Earnings call: Evotec SE meets 2023 guidance, appoints new CEO - Investing.com

Apr 25, 2024
pulisher
Apr 24, 2024

Evotec: Still A Speculative Buy After A Significant Decline (NASDAQ:EVO) - Seeking Alpha

Apr 24, 2024
pulisher
Apr 18, 2024

Evotec and Variant Bio partner to develop fibrosis treatments - Investing.com

Apr 18, 2024
pulisher
Dec 21, 2023

symbol__ Stock Quote Price and Forecast - CNN

Dec 21, 2023

Finanzdaten der Evotec Se Adr-Aktie (EVO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$46.22
price up icon 4.84%
drug_manufacturers_specialty_generic RDY
$13.31
price down icon 1.04%
$22.65
price up icon 0.39%
$10.39
price up icon 0.39%
$139.69
price up icon 1.05%
$449.15
price down icon 1.27%
Kapitalisierung:     |  Volumen (24h):